Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
Open Access
- 1 July 2010
- journal article
- other
- Published by SAGE Publications in Clinical Trials
- Vol. 7 (4), 312-321
- https://doi.org/10.1177/1740774510374973
Abstract
Background A major challenge for randomized phase III oncology trials is the frequent low rates of patient enrollment, resulting in high rates of premature closure due to insufficient accrual. Purpose We conducted a pilot study to determine the extent of trial closure due to poor accrual, feasibility of identifying trial factors associated with sufficient accrual, impact of redesign strategies on trial accrual, and accrual benchmarks designating high failure risk in the clinical trials cooperative group (CTCG) setting. Methods A subset of phase III trials opened by five CTCGs between August 1991 and March 2004 was evaluated. Design elements, experimental agents, redesign strategies, and pretrial accrual assessment supporting accrual predictions were abstracted from CTCG documents. Percent actual/predicted accrual rate averaged per month was calculated. Trials were categorized as having sufficient or insufficient accrual based on reason for trial termination. Analyses included univariate and bivariate summaries to identify potential trial factors associated with accrual sufficiency. Results Among 40 trials from one CTCG, 21 (52.5%) trials closed due to insufficient accrual. In 82 trials from five CTCGs, therapeutic trials accrued sufficiently more often than nontherapeutic trials (59% vs 27%, p = 0.05). Trials including pretrial accrual assessment more often achieved sufficient accrual than those without (67% vs 47%, p = 0.08). Fewer exclusion criteria, shorter consent forms, other CTCG participation, and trial design simplicity were not associated with achieving sufficient accrual. Trials accruing at a rate much lower than predicted (<35% actual/predicted accrual rate) were consistently closed due to insufficient accrual. Limitations This trial subset under-represents certain experimental modalities. Data sources do not allow accounting for all factors potentially related to accrual success. Conclusion Trial closure due to insufficient accrual is common. Certain trial design factors appear associated with attaining sufficient accrual. Defining accrual benchmarks for early trial termination or redesign is feasible, but better accrual prediction methods are critically needed. Future studies should focus on identifying trial factors that allow more accurate accrual predictions and strategies that can salvage open trials experiencing slow accrual. Clinical Trials 2010; 7: 312—321. http://ctj.sagepub.comKeywords
This publication has 22 references indexed in Scilit:
- A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group ProgramJNCI Journal of the National Cancer Institute, 2010
- A systematic review highlights threats to validity in studies of barriers to cancer trial participationJournal of Clinical Epidemiology, 2007
- Strategies to improve recruitment to research studiesPublished by Wiley ,2007
- Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factorsThe Lancet Oncology, 2006
- Barriers and facilitators to enrollment in cancer clinical trialsCancer, 2002
- Public Attitudes Regarding Willingness to Participate in Medical Research StudiesSocial Work in Public Health, 2000
- Barriers to Participation in Randomised Controlled Trials: A Systematic ReviewJournal of Clinical Epidemiology, 1999
- Equipoise and the Ethics of Clinical ResearchThe New England Journal of Medicine, 1987
- Applying results of randomised trials to clinical practice: impact of losses before randomisation.BMJ, 1984